In addition, EMTc share a transcriptomic signature with the recently identified human mesenchymal and stem-like prostate cancer (MSPC) subtype, that is present in treatment-naïve patients, enriched in metastatic prostate cancer, and frequently mutated for PTEN and TP53 [6]. The gene discussed is TP53; the disease is metastatic prostate carcinoma.